Method of restoring endothelium of cornea

Details Method of restoring endothelium of cornea Method of restoring endothelium of cornea

2001-07-05

2003-10-07

Casler, Brian L. (Department: 3763)

Surgery

Means for introducing or removing material from body for...

Treating material introduced into or removed from body...

C128S898000

Reexamination Certificate

active

06629970

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to the field of medicine, in particular, to ophthalmology.
BACKGROUND OF THE INVENTION
It is known that under normal physiological conditions, the mitotic capability of cornea endothelium is limited. Regeneration of the endothelium takes place, as a rule, as a result of hypertrophy and migration of endothelium cells. With age, there is a constant reduction of the number of endothelium cells, and any damage, including surgical trauma, increases the percentage of their loss. A reduction of the density of endothelium cells to below the critical level (less than 1000 cells per mm
2
) results in the development of endothelium-epithelium dystrophy (EED) of the cornea, which means a sharp loss of eyesight and capability of working.
A method of restoring damaged endothelium is known, this method consisting in administering a purified fibroblastic growth factor into the anterior chamber of the eye (Exp. Eye Res., 1987, 45, 805-807). However, the author has only achieved favorable results in experiments.
A drawback of the proposed method is the necessity to introduce a substance of protein nature into the eye cavity, as a result of which an allergic reaction may occur.
The object of the invention is to create a safe and effective method of activating the proliferation of endothelium in order to reduce the loss of endothelium cells during surgical intervention, and also of restoring damaged endothelium of the cornea of a human during post-operation keratopathy and the development of secondary endothelium-epithelium dystrophy.
The technical result of the invention is reduction of the loss of endothelium in the post-operation period, and during post-operation keratopathy and the initial stage of secondary endothelium-epithelium dystrophy are reduction of the edema and normalization of the thickness of the cornea, increase of the density of the endothelium and disappearance of the feeling of discomfort in a patient as a result of activation of the proliferation of endothelium, normalization of the level of hydration and activation of metabolism in the tissue of the cornea, stabilization of cell membranes of the cornea and suppression of the processes of development of inflammation.
SUMMARY OF THE INVENTION
The technical result is achieved in that in a method of restoring the endothelium of the cornea, including administration of an activating solution into the anterior segment of the eye, in accordance with the invention, restoration of the endothelium of the cornea is effected with the aid of an activating solution having the following composition:
carnosine
 0.1-20.0 mg
a complex of glycosaminoglycans with cations
0.005-0.15 mg
of at least one metal of the group consisting of
calcium, magnesium, zinc, aluminum, copper,
iron, manganese in 1 ml of a balanced salt
solution, wherein the activating solution
may additionally contain glycosaminoglycans
in an amount of from 0.005 to 1.0 mg.
in 1 ml of a balanced salt solution, wherein the activating solution may additionally contain glycosaminoglycans in an amount of from 0.005 to 1.0 mg.
The balanced salt solution may be a 0.001-0.01 M phosphate buffer with pH=7.2-7.6 in a 0.14-0.16 M solution of sodium chloride.
DETAILED DESCRIPTION OF THE INVENTION
During extraction of a cataract with implantation of an intraocular lens (IOL) or during implantation of an IOL for refraction, the anterior chamber of the eye is filled with the activating solution after the operation is over, or irrigation with the activating solution in an amount of 20-200 ml is carried out during the whole operation.
In order to reduce the loss of the density of endothelium cells after the operation, the activating solution is administered subconjunctivally with 0.3 ml daily for 3-5 days.
In the case of keratopathy in the post-operation period or during the development of the initial stage of secondary EED, the activating solution is administered subconjunctivally with 0.3 ml daily for 5-10 days or by the phonophoresis method through the cornea in a continuous mode for 10 minutes at an intensity of 0.2-0.3 W/cm
2
with use of 5 ml of the solution daily, wherein 5-8 sessions are carried out.
The activating solution may additionally contain a viscoelastic in an amount of 90-99% by weight and the anterior chamber of the eye is filled with it at the initial stage of the operation.
The complex of glycosaminoglycans (GAGs) with cations of at least one metal from the group consisting of calcium, magnesium, zinc, aluminum, copper, iron, manganese, has a multifactor effect on the cornea of the eye. It is known that cations of metals, which are present in human tissues, activate many biochemical processes. In turn GAGs are inherent components of connective tissue, in particular of the cornea, and actively participate in water-salt metabolism, stimulate the reparation of damaged connective tissue by activating cellular elements, reduce inflammatory reaction. In the case of damage to the connective tissue, the concentration of GAGs in the damage zone is sharply reduced and the additional administration of GAGs promotes active restoration of normal tissue. By nature GAGs are polysaccharides, built from repeating disaccharide components which usually contain ammo sugar and uronic acid. Keratan sulfate, hondroitin sulfate, heparin, heparan sulfate, hyaluronic acid, dermatan sulfate relate to GAGs. All the GAGs are polyanions due to the presence in their structure of acid sulfate groups or carboxy groups of uronic acids.
The GAG complex with metal cations, which is prepared under conditions corresponding to physiological (osmomolarity and pH equal to those of tissue liquid), is an adequately natural carrier of cations which are necessary for activation of biochemical processes, in particular to increase the mobility of endothelium cells—a necessary composite part of the regeneration process.
Experiments, which we have conducted on the eyes of rabbits, have shown that the administration of a complex of GAGs with cations of metals into the anterior segment of the eye after a dosed trauma of the endothelium results in intensification of the proliferation of endothelium cells. During incubation of a donor cornea of a person with a dosed trauma of endothelium in a solution of a complex of GAGs with cations of metals, a substantial reduction of the area of the zone deprived of endothelium, the appearance of mitosis figures in cells were observed with the subsequent normalization of the density of endothelium cells in that zone, which indicates the presence of the process of proliferation of endothelium. The observed effect may be related to activation of the fibroblastic growth factor, which is contained in the descemetic membrane in an inactive form.
In order to prepare a complex of GAG with metal cations, it is most preferable to use heparin, including its low-molecular fractions (so-called low-molecular heparin) and GAGs separated from eye tissue, for example from the cornea or from a vitreous body. Wherein, a mixture of GAGs may be used with any weight ratios of concrete representatives of the class of GAGs.
The complex of GAGs with metal cations is prepared in the following manner. At least one of the water-soluble salts of metal cations (for example, calcium chloride, magnesium chloride, zinc sulfate, aluminum sulfate, copper sulfate, ferric chloride, manganese chloride) in an amount five times by weight in excess is added to a GAG solution with a concentration of from 0.5 to 20 mg/ml in a 0.15 M Tris-HCl buffer, pH 7.2-7.6, mixed and left at 4-8° C. for 24 hours. The complex of GAGs with cations of metals is separated by means of gelchromatography, freeing from the low-molecular impurities. The concentration of the prepared solution of the complex is measured spectrophotometrically at a wavelength of 535 nm with 1,9-dimethylene blue dye (Connective Tissue Research, 1982, v. 9, pp. 247-248). Then the components of the activating solution in the concentrations according to the claims are mixed.
Carnosine—a histidine-containing dipeptide,

Affiliated with

Also associated with

Rating

Method of restoring endothelium of cornea does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of restoring endothelium of cornea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of restoring endothelium of cornea will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3127782